Sma clinical trials

Explore recruiting sma clinical trials.

Recruiting sma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Sma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of NMD670 in ambulatory adults with Type 3 spinal muscular atrophy

Netherlands, Spain, Belgium, Denmark, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Longitudinal study of clinical outcome measures in adult patients with Spinal Muscular Atrophy (SMA) treated with Risdiplam.

Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric patients with Spinal Muscular Atrophy

Netherlands, Italy, France, Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam - ASCEND

Germany, Italy, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants with Spinal Muscular Atrophy

Norway, Italy, Belgium, Germany, Poland, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Patients with Spinal Muscular Atrophy After Gene Therapy

Germany, Poland

Therapeutic use (Phase IV) EU CTIS Study details

Sma trials by city

Sma in Toronto Sma in Vancouver Sma in Montreal Sma in Calgary Sma in Edmonton Sma in Ottawa Sma in Winnipeg Sma in Quebec City Sma in Hamilton Sma in Kitchener Sma in London Sma in Halifax Sma in New York Sma in Los Angeles Sma in Chicago Sma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease